DIANTHUS THERAPEUTICS

Dianthus Therapeutics Appoints Simon Read, Ph.D., to Board of Directors

22 May 2025 13:10:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

12 May 2025 13:01:46 By Nasdaq GlobeNewswire

Dianthus Therapeutics Completes Enrollment of Phase 2 MaGic Trial of DNTH103 in Generalized Myasthenia Gravis With Top-Line Results Expected in September

05 May 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Two Upcoming Investor Events

29 Apr 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q4 and FY 2024 Financial Results

11 Mar 2025 13:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Strengthens Strategic Commercial Leadership With Appointment of John C. King as Chief Commercial Officer and Welcomes Sujay Kango, A Seasoned Commercial Leader, to Board of Directors

05 Mar 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Two Upcoming Investor Conferences

26 Feb 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Webcast Presentations at Two Investor Conferences

30 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Webcast Presentation at the 43rd Annual J.P. Morgan Healthcare Conference

08 Jan 2025 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q3 Financial Results

07 Nov 2024 13:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Three Upcoming Healthcare Investor Conferences

04 Nov 2024 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 2024 American Association of Neuromuscular and Electrodiagnostic Medicine (AANEM) Annual Meeting

15 Oct 2024 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in Three Healthcare Investor Conferences in September

04 Sep 2024 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q2 Financial Results

08 Aug 2024 13:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Two Poster Presentations for DNTH103 at the 10th Congress of the European Academy of Neurology (EAN)

28 Jun 2024 08:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces FDA Clearance to Initiate Phase 2 Trial of DNTH103 in Multifocal Motor Neuropathy (MMN)

12 Jun 2024 04:00:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Jefferies Global Healthcare Conference

30 May 2024 13:30:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results

09 May 2024 13:01:00 By Nasdaq GlobeNewswire

Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference

08 May 2024 13:30:54 By Nasdaq GlobeNewswire

Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

03 May 2024 13:30:00 By Nasdaq GlobeNewswire